New drug combo aims to speed immune recovery after stem cell transplant

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Treatment Portion: * AML in 1st remission - for patients whose AML does not have "good risk" cytogenetic features (i.e. t (8;21), t(15;17), inv 16 without c-kit mutations). * Acute leukemias of ambiguous lineage in ≥ 1st remission * Secondary AML in remission * AML in ≥ 2nd remission * ALL in 1st remission with clinical or molecular features indicating a high risk for relapse; or ALL ≥ 2nd remission * CML failing to respond to or not tolerating imatinib, dasatinib or nilotinib in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in CR after accelerated phase or blast crisis. * Non-Hodgkins lymphoma with chemo responsive disease in any of the following categories: intermediate or high grade lymphomas who have failed to achieve a first CR or have relapsed following a 1st remission who are not candidates for autologous transplants. b.ii. any NHL in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant. * Myelodysplastic syndrome (MDS): RA/RCMD with high risk cytogenetic features or transfusion dependence, RAEB-1 and RAEB-2 * Chronic myelomonocytic leukemia: CMML-1 and CMML-2. * Patient's age is ≥18 or ≤60 years old * Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status ≥ 70% * Patients must have adequate organ function measured by: Cardiac: asymptomatic or if symptomatic then LVEF at rest must be \> 50% and must improve with exercise. * Pulmonary: asymptomatic or if symptomatic, DLCO \> 60% of predicted (corrected for hemoglobin) * Hepatic: \< 3xULN ALT and \< 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia * Renal: serum creatinine \< 1.2 mg/dL or if serum creatinine is outside the normal range, the CrCl \> 50 ml/min (measured or calculated/estimated) * Patients have a plan to receive a CD34-selected peripheral blood stem cell transplant with TBI-based conditioning. Exclusion Criteria: * Active extramedullary disease * Active and uncontrolled infection at time of transplantation * Patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months. * Pregnant or breast feeding * HIV infection * Patient is felt to not be a candidate for TBI by the BMT service Donor Inclusion Criteria: * Donor must be willing and able to undergo PBSC collection.